Molecular characterization of the anticancer properties associated with bee venom and its components in glioblastoma multiforme.
Antineoplastic Agents
/ therapeutic use
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Survival
/ drug effects
Drug Synergism
Gene Expression Regulation, Neoplastic
/ drug effects
Glioblastoma
/ drug therapy
Humans
Lymphocytes
/ drug effects
Melitten
/ therapeutic use
Monocytes
/ drug effects
Necrosis
/ drug therapy
Phospholipases A2
/ therapeutic use
RNA, Long Noncoding
/ metabolism
Temozolomide
/ therapeutic use
Apitoxin
Apoptosis
Brain tumor
Cancer
Glioma
Non-coding RNAs
Journal
Chemico-biological interactions
ISSN: 1872-7786
Titre abrégé: Chem Biol Interact
Pays: Ireland
ID NLM: 0227276
Informations de publication
Date de publication:
25 Sep 2021
25 Sep 2021
Historique:
received:
19
11
2020
accepted:
04
08
2021
pubmed:
11
8
2021
medline:
18
9
2021
entrez:
10
8
2021
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is a frequent form of malignant glioma. Strategic therapeutic approaches to treat this type of brain tumor currently involves a combination of surgery, radiotherapy and chemotherapy. Nevertheless, survival of GBM patients remains in the 12-15 months range following diagnosis. Development of novel therapeutic approaches for this malignancy is therefore of utmost importance. Interestingly, bee venom and its components have shown promising anti-cancer activities in various types of cancer even though information pertaining to GBMs have been limited. The current work was thus undertaken to better characterize the anti-cancer properties of bee venom and its components in Hs683, T98G and U373 human glioma cells. MTT-based cell viability assays revealed IC
Identifiants
pubmed: 34375656
pii: S0009-2797(21)00260-X
doi: 10.1016/j.cbi.2021.109622
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
RNA, Long Noncoding
0
Melitten
20449-79-0
Phospholipases A2
EC 3.1.1.4
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109622Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.